Immune-Mediated Optic Neuropathy in Chronically Immunosuppressed Transplant Patients

Le résumé fourni par la source

Chronic immunosuppression is critical in solid organ transplant patients to prevent graft rejection. Although it would seem logical to assume that these chronic and aggressive immunosuppressive regimens would suppress or prevent acute inflammatory disease producing visual loss, we report 4 such cases of acute inflammatory optic neuropathy in chronically immunosuppressed patients. To the best of our knowledge, these are the first such reports in the English language ophthalmic literature. These cases raise the question of whether immune-specific regimens can worsen other immunologic mechanisms of disease that are not being suppressed. CASE 1 A 74-year-old Caucasian woman presented with acute painless loss of vision in the left eye. The medical history was significant for liver transplant and chronic immunosuppressive therapy with tacrolimus. On examination, the visual acuity was no light perception (NLP) in the right eye due to previous long standing and stable herpetic infection with secondary retinal detachment several years ago. The vision measured 20/80 in the left eye and was decreased from her previous baseline of 20/30 vision in the left eye. Humphrey visual field testing (24-2 HVF) demonstrated a superior and inferior arcuate defect in the left eye. The right anterior segment showed a markedly thickened cornea because of chronic stromal edema with an intact corneal epithelium in the right eye. The anterior chamber was flat and there was a dense iris membrane and marked chronic posterior synechiae in the right eye. The slit-lamp examination in the left eye was normal. There was no view of the fundus in the right eye. Dilated fundus examination in the left eye showed multifocal dot and blot hemorrhages and vascular narrowing with a cup-to-disc ratio of 0.8. The optic nerve was sharp and there was no edema or pallid edema. Fundus fluorescein angiogram showed markedly delayed arteriovenous transit time, intraretinal hemorrhages, venous dilation, and multifocal cotton wool spots in the left eye. This was believed to be consistent with an ocular ischemic image of the left eye. No Hollenhorst plaques were seen. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) measured 26 mm/hour and 0.53 mg/dL, respectively. She was admitted to the hospital and received intravenous methylprednisolone (IVMP), and a temporal artery biopsy showed disruption of the internal elastic lamina and CD68+ histiocytes consistent with giant cell arteritis (GCA). The patient was discharged after 5 doses of IVMP on oral prednisolone and on follow-up examination 3 months later had 20/20 vision in the left eye with resolution of the posterior segment findings (and a stable NLP vision in the right eye). She was continued on a tapering dose of long-term steroids for biopsy proven GCA. CASE 2 A 68-year-old Caucasian man presented with chronic and progressive visual loss in both eyes. He had been on chronic immunosuppressive therapy with tacrolimus, mycophenolate, and a low-dose prednisone status after bilateral lung transplant for 6 years. The lung transplant was performed for idiopathic pulmonary fibrosis. In addition to the progressive vision loss, he had hearing loss, ataxia, neurogenic bladder, and peripheral neuropathy worse on the left. Subsequent MRI demonstrated longitudinally extensive transverse myelitis (LETM) with T2 hyperintensity across 3 vertebral segments (C3, C4, and C5) and subtle enhancement in the posterior cervical cord at the lower C3 to upper C4 levels. The patient was referred for neuro-ophthalmology evaluation 7 months after the onset of visual loss. On examination, his visual acuity was 20/125 in the right eye and 20/100 in the left eye. Humphrey visual field (24-2 HVF) showed generalized depression in the right eye and a temporal nerve fiber defect in the left eye (Fig. 1). External, anterior segment and intraocular pressure examinations were normal in both eyes. Dilated fundus examination showed bilateral diffuse optic atrophy. The patient was admitted to the hospital and continued with 5-mg oral prednisone and 2.5-mg oral tacrolimus. Electromyography (EMG) was performed and suggested overall moderately severe axonal sensory-motor neuropathy with preference to the right. Lumbar puncture demonstrated an elevated protein level of 60 mg/dL (normal range 15–45 mg/dL) in the cerebrospinal fluid (CSF). Antimyelin oligodendrocyte glycoprotein and neuromyelitis optica (NMO) antibodies (i.e., aquaporin-4 antibodies) were negative. An MRI of the orbit with gadolinium showed potential left optic nerve atrophy that was confirmed with an ophthalmoscope. Other causes of optic neuropathy and LETM were ruled out—specifically vitamin B12, varicella zoster virus, neurosyphilis, and CSF cell count with differential were all normal or negative. A paraneoplastic panel including CRMP5 antibody was checked and came back negative. He received a five-day course of IVMP and intravenous immunoglobulin (IVIg). At his most recent neurology appointment 9 months after presentation, the neurogenic bladder, hearing loss, and neuropathic symptoms seemed stable; however, his ataxia had progressed to a nonambulatory state. Potential causes of the hearing loss and axonal sensory-motor peripheral neuropathy were explored—laboratory results showed a normal B12, hemoglobin A1c, B1, anti-nuclear antibody, and thyroid-stimulating hormone. However, there was a significant alcohol use history. He was transferred to a rehabilitation unit, and tacrolimus and mycophenolate were discontinued, and cyclosporine was initiated for a seronegative NMO spectrum disorder (1).FIG. 1.: Humphrey visual fields (24-2 HVF), Case 2. Note generalized depression in the right eye and a greater temporal visual field defect than a nasal visual field defect in the left eye.CASE 3 A 54-year-old Caucasian man presented with bilateral, painless, progressive visual loss. The medical history was significant for biopsy-proven sarcoidosis status after pulmonary transplantation with chronic rejection on chronic immunosuppression with tacrolimus and 10 mg of prednisone daily and graft-vs-host disease status after plasmapheresis and stem cell transplantation. He was treated with IV steroids, but his vision did not improve. On referral to the neuro-ophthalmology service, his visual acuity was hand motions in each eye. The pupils were poorly reactive bilaterally. Slit-lamp examination showed pseudophakia and no evidence for anterior or posterior uveitis. No intraocular granulomatous disease was seen. Ophthalmoscopy showed diffuse optic atrophy in both eyes. The patient was readmitted to the hospital with initiation of high-dose IV steroids. MRI of the brain and orbits with and without contrast showed increased T2 signal in the optic chiasm and bilateral optic tracts. Chest x-ray showed scarring and granulomatous calcifications adjacent to the left hilum. The patient received IVIg for 4 days and the vision remained stable. CASE 4 A 76-year-old African American woman on chronic immunosuppression with sirolimus and tacrolimus status after heart transplant 8 years before due to extensive coronary artery disease presented to the ophthalmology clinic with painful, bilateral, progressive blurring of vision, headache, weight loss, and scalp tenderness for the past 4 months. Examination showed visual acuity of 20/25 in the right eye and 20/40 in the left eye with no anisocoria or relative afferent pupillary defect. Fields were full to confrontation. Dilated fundus examination demonstrated mild pallor of both optic nerves. The ESR and CRP were within normal limits. She underwent a left temporal artery biopsy that showed irregular intimal hyperplasia associated with the focal absence of internal elastic lamina. There was no lymphocytic or giant cell infiltrate in the wall of the artery. The Movat pentachrome staining showed a focal segmental absence of the elastic lamina and focal fibrosis of the muscularis under this area. CD68 I

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.